Have swab, will travel
PDI offers the Chlorascrub swab, the first 3.15% chlorhexidine gluconate and 70% isopropyl alcohol pre-injection skin antiseptic for inclusion in kits for various medical procedures. Specially designed packaging protects the swab during the ethylene oxide sterilization process of finished kits. PDI will also continue to offer its nonkit Chlorascrub swab.
Information: http://www.nursingcenter.com/nmie/upfront
Get organized!!
EPS, Inc., has expanded its line of storage and transport items to include unit dose and medication exchange bins for the efficient handling of unit dose medication and I.V. bags; bulk supply tubs for large, unwieldy items; durable stock bins for transporting small products; autoclavable instrument trays for delicate instruments and supplies requiring special handling; and mobile utility workstation carts to move both work areas and supplies at the same time.
Information: http://www.nursingcenter.com/nmie/upfront
The power of collagen
Pegasus Biologics introduces the Unite Biomatrix wound dressing for the local management of moderate to heavy exudating wounds, including partial- and full-thickness wounds, draining wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds, and surgical wounds.
The dressing is stable, strong, thin and comfortable, easy to store, and available in sizes up to 9 cm x 9 cm. It also has a convenient 2-year room-temperature shelf life.
http://www.nursingcenter.com/nmie/upfront
A chair of many hats
The MC675M Motorized Stretchair from Stretchair Patient Transfer Systems, Inc., is a self-contained transportation system that functions in both chair and stretcher modes. Key features include a 675-pound (306 kg) weight capacity, a 28-inch (71 cm) seat width, Tempur-Med pressure management cushions, integrated handset controller for all powered functions (including sit-to-stand seat assist), chair-to-stretcher articulation, independent swing legs, and vertical lift. It can be used as a gurney, wheelchair, standing/lifting aid, short-term bed, and for performing minor procedures and exams. In this way, the MC675M Stretchair can replace the need for multiple pieces of equipment.
Information: http://www.nursingcenter.com/nmie/upfront
This pen has a memory
Eli Lilly launches its prescription HumaPen Memoir/Luxura HD insulin pen with digital memory capability for use with the company's insulin lispro injection (rDNA origin) 3-mL cartridges (Humalog). The device is intended to simplify daily management of diabetes for people who take several injections of mealtime insulin each day. It features a consumer-friendly "push to know" digital display that lets patients record and review the last 16 insulin doses, including the priming doses.
A smaller version of the pen (HumaPen Luxura HD) is also expected to be available by prescription. The reusable device, which can deliver 1 to 30 units of insulin lispro in half-unit increments, can be useful to children and other patients who don't use large amounts of insulin.
Information: http://www.nursingcenter.com/nmie/upfront
Making enteral feeding safer
Exacta-Med enteral syringes from Baxa Corp. are the first medication syringes designed only for enteral feeding, featuring a unique, non-luer tip that won't accept a hypodermic needle or actuate a needleless I.V. access port. Orange lettering corresponds with enteral tube sets to prevent wrong-route administration. Created in response to The Joint Commission and National Health Service alerts about the risk of tubing and catheter misconnection errors, these syringes are available in 20-, 35-, and 60-mL sizes and come individually packaged to reduce the risk of contamination.
Information: http://www.nursingcenter.com/nmie/upfront
this just in [horizontal ellipsis]
A recent report has raised concerns about the risk of heart attack associated with rosiglitazone maleate (Avandia). But interim data from a prospective clinical trial (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes, or RECORD), which was designed to evaluate cardiovascular outcomes in more than 4,000 patients with type 2 diabetes, show no significant difference between the Avandia group and control groups in incidence rate of heart attack and death due to cardiovascular events. Patients taking Avandia did have a higher incidence rate of congestive heart failure than patients in the control groups; however, no difference was seen between the Avandia group and the control group in the key outcome of cardiovascular hospitalizations and death. The U.S. Food and Drug Administration will continue to weigh data from several sources and recommends that patients taking Avandia who are at high risk for heart attack should talk to their health care providers about all available treatment options for type 2 diabetes.